Have a feature idea you'd love to see implemented? Let us know!

NERV Minerva Neurosciences Inc

Price (delayed)

$2.12

Market cap

$14.83M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.45

Enterprise value

-$11.8M

Minerva's portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia, and MIN-301, in pre-clinical development for Parkinson's disease.

Highlights
The company's net income has surged by 90% QoQ and by 88% YoY
The EPS has surged by 90% year-on-year and by 90% since the previous quarter
Minerva Neurosciences's equity has surged by 51% QoQ but it has decreased by 8% YoY
The company's quick ratio has shrunk by 58% YoY and by 19% QoQ

Key stats

What are the main financial stats of NERV
Market
Shares outstanding
6.99M
Market cap
$14.83M
Enterprise value
-$11.8M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
Gross profit
$0
Net income
-$3.31M
EBIT
-$3.31M
EBITDA
-$3.28M
Free cash flow
-$20.38M
Per share
EPS
-$0.45
EPS diluted
-$0.45
Free cash flow per share
-$2.69
Book value per share
-$3.1
Revenue per share
$0
TBVPS
$3.69
Balance sheet
Total assets
$42.81M
Total liabilities
$64.48M
Debt
$0
Equity
-$21.67M
Working capital
$23.45M
Liquidity
Debt to equity
0
Current ratio
6.23
Quick ratio
5.94
Net debt/EBITDA
8.11
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-6.7%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-8.6%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NERV stock price

How has the Minerva Neurosciences stock price performed over time
Intraday
0%
1 week
-7.42%
1 month
-5.36%
1 year
-69.01%
YTD
-65.53%
QTD
-20.6%

Financial performance

How have Minerva Neurosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$24.5M
Net income
-$3.31M
Gross margin
N/A
Net margin
N/A
The company's net income has surged by 90% QoQ and by 88% YoY
NERV's operating income is down by 17% year-on-year but it is up by 7% since the previous quarter

Growth

What is Minerva Neurosciences's growth rate over time

Valuation

What is Minerva Neurosciences stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has surged by 90% year-on-year and by 90% since the previous quarter
Minerva Neurosciences's equity has surged by 51% QoQ but it has decreased by 8% YoY

Efficiency

How efficient is Minerva Neurosciences business performance
Minerva Neurosciences's return on assets has surged by 89% QoQ and by 86% YoY

Dividends

What is NERV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NERV.

Financial health

How did Minerva Neurosciences financials performed over time
The total assets is 34% less than the total liabilities
The company's quick ratio has shrunk by 58% YoY and by 19% QoQ
Minerva Neurosciences's current ratio has shrunk by 57% YoY and by 17% QoQ
The debt is 100% more than the equity
Minerva Neurosciences's equity has surged by 51% QoQ but it has decreased by 8% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.